<?xml version="1.0" encoding="UTF-8"?>
<p id="p0150">Various major vaccine development platforms are advancing with their nucleic acid-based therapeutic models towards its clinical testing and evaluation [
 <xref rid="bib58" ref-type="bibr">58</xref>]. The prime characteristics of the vaccine development include the cost, flexibility, speed, immunogenicity, reactogenicity, and safety of the manufacture [
 <xref rid="bib133" ref-type="bibr">133</xref>]. The vaccine stability and durability are also of prime concern in vaccine development. Currently, several companies like Moderna, Inovio, BioNtech, and Curevac have taken initiatives to develop a potential therapeutic strategy against COVID-19, which involves the use of nucleic acid molecules [
 <xref rid="bib134" ref-type="bibr">134</xref>]. Moderna Inc. USA, Inovio Pharmaceuticals, USA and Pfizer in collaboration with BioNTECH, has selected mRNA-1273, INO-4800 DNA vaccine and BNT162 mRNA vaccine, respectively as vaccine candidates for trial against COVID-19 [
 <xref rid="bib134" ref-type="bibr">134</xref>].
</p>
